6. Antibody-Drug Conjugates
Most new treatment advances this year involved targeted therapies and immunotherapies—but don’t count chemotherapy out yet. Several new medications use monoclonal antibodies to deliver cell-killing chemo drugs directly to tumors, which helps spare healthy cells and reduce side effects. These antibody-drug conjugates include Polivy (polatuzumab vedotin) for B-cell lymphoma, Padcev (enfortumab vedotin) for bladder cancer and the brand-new Enhertu (fam-trastuzumab deruxtecan), which joins Kadcyla (ado-trastuzumab emtansine) as an option for HER2-positive breast cancer.
